BIOMARIN PHARMACEUTICAL INC

Pharmaceutical Preparations·NOVATO, CA·FY end 12/31·CIK 1048477

CEO Pay Ratio

109:1

Alexander Hardy

CEO Total Comp

$21.9M

Alexander Hardy

Median Employee

$201,036

Revenue

$3.2B

FY 2025

Net Income

$348.9M

FY 2025

Free Cash Flow

$725.0M

FY 2025

Net Margin

10.8%

Insider Net (180d)

-$3.0M

0 buys / 3 sales

CEO Pay Accountability

CEO comp as % of net income

6.28%

For every $1,000 of profit, $62.85 flows to the CEO.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$3.2B	$2.9B	$2.4B	$2.1B	$1.8B
Gross Profit	—	—	—	—	—	—
Operating Income	$409.5M	$484.2M	$158.1M	$149.6M	-$82.3M
Net Income	$348.9M	$426.9M	$167.6M	$141.6M	-$64.1M
Operating CF	$828.0M	$572.8M	$159.3M	$175.9M	$304.5M
Capex	$103.0M	$85.4M	$96.7M	$121.0M	$95.6M
Free Cash Flow	$725.0M	$487.4M	$62.6M	$54.9M	$209.0M
Buybacks	—	—	—	$0	$0
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	12.7%	17.0%	6.5%	7.1%	-4.5%
Net Margin	10.8%	15.0%	6.9%	6.8%	-3.5%
FCF Margin	22.5%	17.1%	2.6%	2.6%	11.3%
R&D / Revenue	28.6%	26.2%	30.9%	31.0%	34.1%
Effective Tax	27.7%	21.2%	11.1%	5.4%	15.0%
Debt / Equity	—	—	—	—	—	—
Buybacks / FCF	—	—	—	0.0%	0.0%

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Alexander HardyPresident and CEO	$1.1M	$16.8M	$1.9M	$1.6M	$409.4K	$21.9M
Gregory R. FribergM.D. Executive Vice President, Chief Research & Development Officer	$705.7K	$4.6M	$1.3M	$424.2K	$153.2K	$7.2M
Brian R. MuellerExecutive Vice President, CFO	$721.2K	$4.3M	$1.2M	$565.5K	$22.9K	$6.8M
Cristin HubbardExecutive Vice President, Chief Commercial Officer	$662.3K	$3.5M	$954.8K	$562.8K	$69.6K	$5.7M
C. Greg GuyerPh.D. Executive Vice President, Chief Technical Officer	$697.1K	$3.5M	$954.8K	$546.0K	$29.6K	$5.7M